In fact, recent studies have shown that the expression status of a glutamine transporter, solute carrier 1 family member 5 (SLC1A5), in human colorectal cancer patients dictates their response to cetuximab regardless of EGFR/KRAS mutational status, thus highlighting the importance of currently unknown/unrecognized novel molecular pathways driving cetuximab resistance8,9. The gene discussed is SLC1A5; the disease is colorectal cancer.